公开(公告)号：US5429940A

公开(公告)日：1995-07-04

申请号：US060240

申请日：1993-07-12

申请人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh ,  Hisao Kobayashi ,  Toshio Nagai ,  Kazuhiro Sugamura

发明人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh ,  Hisao Kobayashi ,  Toshio Nagai ,  Kazuhiro Sugamura

IPC分类号： C07D498/14 ,  C12P17/18 ,  A61K31/435 ,  C12P17/16

CPC分类号： C07D498/14 ,  C12P17/188 ,  Y10S435/822 ,  Y10S435/863

摘要： The present invention provides a process for producing oxazopyrroloquinolines which comprises culturing microorganisms to produce pyrroloquinolinequinone and adding .alpha.-amino acids or monomethylamine to the resulting culture broth which contains the pyrroloquinolinequinone and from which cells of microorganisms are not separated, thereby to convert the pyrroloquinolinequinone to the corresponding oxazopyrroloquinolines. The thus obtained oxazopyrroloquinolines include novel compounds. The present invention further provides aldose reductase inhibitors, diabetic combined disease curing agents, immunopotentiating agents and liver disease inhibiting agents which contain as active ingredient these oxazopyrroloquinolines having excellent physiological activity.

摘要翻译： 本发明提供一种生产恶唑并吡咯并喹啉的方法，其包括培养微生物以产生吡咯并喹啉醌，并向所得的含有吡咯并喹啉醌的培养液中加入α-氨基酸或一甲基胺，并且微生物细胞未分离，从而将吡咯并喹啉醌转化为 对应的恶唑并吡咯啉喹啉。 由此获得的恶唑并吡咯啉喹啉包括新化合物。 本发明还提供了具有优异生理活性的醛糖还原酶抑制剂，糖尿病合并疾病固化剂，免疫增强剂和肝病抑制剂，其含有作为活性成分的恶唑吡咯并喹啉。

公开(公告)号：US5236930A

公开(公告)日：1993-08-17

申请号：US826220

申请日：1992-01-23

申请人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh ,  Hisao Kobayashi ,  Toshio Nagai ,  Kazuhiro Sugamura

发明人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh ,  Hisao Kobayashi ,  Toshio Nagai ,  Kazuhiro Sugamura

IPC分类号： C07D498/14 ,  C12P17/18

CPC分类号： C07D498/14 ,  C12P17/188 ,  Y10S435/822 ,  Y10S435/863

摘要： The present invention provides a process for producing oxazopyrroloquinolines which comprises culturing microorganisms to produce pyrroloquinolinequinone and adding .alpha.-amino acids or monomethylamine to the resulting culture broth which contains the pyrroloquinolinequinone and from which cells of microorganisms are not separated, thereby to convert the pyrroloquinolinequinone to the corresponding oxazopyrroloquinolines.The thus obtained oxazopyrroloquinolines include novel compounds.The present invention further provides aldose reductase inhibitors, diabetic combined disease curing agents, immunopotentiating agents and liver disease inhibiting agents which contain as active ingredient these oxazopyrroloquinolines having excellent physiological activity.

摘要翻译： 本发明提供一种生产恶唑并吡咯并喹啉的方法，其包括培养微生物以产生吡咯并喹啉醌，并向所得的含有吡咯并喹啉醌的培养液中加入α-氨基酸或一甲基胺，并且微生物细胞未分离，从而将吡咯并喹啉醌转化为 对应的恶唑并吡咯啉喹啉。 由此获得的恶唑并吡咯啉喹啉包括新化合物。 本发明还提供了具有优异生理活性的醛糖还原酶抑制剂，糖尿病合并疾病固化剂，免疫增强剂和肝病抑制剂，其含有作为活性成分的恶唑吡咯并喹啉。

公开(公告)号：US5061711A

公开(公告)日：1991-10-29

申请号：US592266

申请日：1990-10-03

申请人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh

发明人： Teizi Urakami ,  Mitsunori Oda ,  Chieko Itoh

IPC分类号： A61K31/47

CPC分类号： A61K31/47

摘要： Disclosed is a method of curing liver diseases by administration of pyrrolo quinoline quinon triesters (PQQ triesters). The PQQ triesters include PQQ triallyl ester and PQQ tribenzyl ester which are novel. The PQQ triesters being ester form, they have no toxicity and can be orally adminstered.